AMD reserved capacity and planned build-out
Company: Core Scientific
The claim, verbatim
Core Scientific management points to AMD's sizeable reserved capacity and planned build-out as a potential offset to its CoreWeave concentration risk.
Source (primary)
What Does Core Scientific (CORZ) Need To Prove As Customer Risk Shifts? - Simply Wall Street (-, news_article)
View cached copy (2026-10-15)Live source ↗Archive.org ↗
Quote: “Management highlights AMD's sizeable reserved capacity and planned build out as a potential offset to CoreWeave related concentration risk.”
How we checked this
Checked on October 16, 2026. The cited source supports every part of this claim.
The article says management highlights AMD's sizeable reserved capacity and planned build out as a potential offset to CoreWeave related concentration risk.
Confirmed in the source:
- Core Scientific management highlights AMD's sizeable reserved capacity and planned build-out
- Management presents this as a potential offset to CoreWeave-related concentration risk
What we did: Read our cached copy of the publisher (https://simplywall.st/stocks/us/software/nasdaq-corz/core-scientific/news/what-does-core-scientific-corz-need-to-prove-as-customer-ris) in full (11,790 characters, retrieved October 15, 2026) and checked each assertion in the claim against it.
Additional evidence
confirms What Does Core Scientific (CORZ) Need To Prove As Customer Risk Shifts? - Simply Wall Street
Quote: “Management highlights AMD's sizeable reserved capacity and planned build out as a potential offset to CoreWeave related concentration risk.”